This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Donald R. Hoover, PhD; Yun Peng, MS; Alfred Saah, MD; Richard Semba, MD; Roger R. Detels, MD; Charles R. Rinaldo, Jr, PhD; John P. Phair, MD

Arch Ophthalmol. 1996;114(7):821-827.

Abstract
Objective
To estimate the incidence and prevalence of cytomegalovirus retinitis (CMV-R) in late-stage human immunodeficiency virus type 1 disease.

Design
Cohort study.

Setting
The Multicenter AIDS Cohort Study, an ongoing 10-year study of human immunodeficiency virus type 1-infected homosexual men with semiannual visits and CD4+ cell testing.

Study Participants
Three hundred sixty-seven human immunodeficiency virus type 1-infected men from the Multicenter AIDS Cohort Study who were receiving zidovudine and Pneumocystis carinii prophylaxis and who had CD4+ cell counts fall below 0.10x10⁹/L(100/µL).

Main Outcome Measures
Kaplan-Meier—type estimates for various longitudinal quantifications of incidence and prevalence of CMV-R were obtained.

Results
Among these 367 individuals, cytomegalovirus disease developed in 103, of whom 73 (71%) had ocular complications. At 4 years after the first CD4 cell count (<0.1 10x10⁹/L), the probability for these subjects to have (1) remained living without CMV-R was 11%, (2) died without experiencing CMV-R was 66%, (3) experienced CMV-R and be living was 6%, and (4) experienced CMV-R and died was 18%. During these 4 years, there was a 25% chance for the development of CMV-R and, on average, 0.211 person-years of CMV-R morbidity. Among those subjects in whom CMV-R developed, about 19% did have CMV-R before a CD4+ cell count of less than 0.05 x10⁹/L (<50/µL) was observed, and 81% had CMV-R after the CD4+ cell count reached this threshold.

Conclusion
These estimates may be relevant to current clinical practice and help in allocating resources and planning for treatment and prophylaxis against cytomegalovirus disease.

Author Affiliations
From the Department of Epidemiology, School of Public Health (Drs Hoover and Saah and Ms Peng), and Department of Ophthalmology, School of Medicine (Dr Semba), The Johns Hopkins University, Baltimore, Md; the Department of Epidemiology, Schools of Public Health and Medicine, University of California—Los Angeles (Dr Detels); the Department of Pathology, Graduate School of Public Health, University of Pittsburgh (Pa) (Dr Rinaldo); and the Howard Brown Memorial Clinic and Department of Medicine, Northwestern University Medical School, Chicago, Ill (Dr Phair).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

AIDS and Ophthalmology, 2008
Jabs
Arch Ophthalmol 2008;126:1143-1146.
FULL TEXT  

Modelling cytomegalovirus replication patterns in the human host: factors important for pathogenesis
Regoes et al.
Proc R Soc B 2006;273:1961-1967.
ABSTRACT | FULL TEXT  

AIDS and Ophthalmology in 2004
Jabs
Arch Ophthalmol 2004;122:1040-1042.
FULL TEXT  

Risk of Vision Loss in Patients With Cytomegalovirus Retinitis and the Acquired Immunodeficiency Syndrome
Kempen et al.
Arch Ophthalmol 2003;121:466-476.
ABSTRACT | FULL TEXT  

Ocular disease in patients with tuberculosis and HIV presenting with fever in Africa
Beare et al.
Br J Ophthalmol 2002;86:1076-1079.
ABSTRACT | FULL TEXT  

Up-Regulation of Fas Ligand Expression by Human Cytomegalovirus Immediate-Early Gene Product 2: A Novel Mechanism in Cytomegalovirus-Induced Apoptosis in Human Retina
Chiou et al.
J. Immunol. 2001;167:4098-4103.
ABSTRACT | FULL TEXT  

Discontinuing anticytomegalovirus therapy in patients with cytomegalovirus retinitis and AIDS
JABS
Br J Ophthalmol 2001;85:381-382.
FULL TEXT  

Retinal Detachment Risk in Cytomegalovirus Retinitis Related to the Acquired Immunodeficiency Syndrome
Kempen et al.
Arch Ophthalmol 2001;119:33-40.
ABSTRACT | FULL TEXT  

Murine Cytomegalovirus Infection Causes Apoptosis of Uninfected Retinal Cells
Bigger et al.
IOVS 2000;41:2248-2254.
ABSTRACT | FULL TEXT  

Entry of Human Cytomegalovirus into Retinal Pigment Epithelial and Endothelial Cells by Endocytosis
Bodaghi et al.
IOVS 1999;40:2598-2607.
ABSTRACT | FULL TEXT  

Protection against Murine Cytomegalovirus Retinitis by Adoptive Transfer of Virus-Specific CD8+ T Cells
Bigger et al.
IOVS 1999;40:2608-2613.
ABSTRACT | FULL TEXT  

Comparison of Cytomegalovirus Loads in Plasma and Leukocytes of Patients with Cytomegalovirus Retinitis
Jabs et al.
J. Clin. Microbiol. 1999;37:1431-1435.
ABSTRACT | FULL TEXT  

Treatment of immune recovery vitritis with local steroids
Henderson and Mitchell
Br J Ophthalmol 1999;83:540-545.
ABSTRACT | FULL TEXT  

Role of IFN-{gamma}-Induced Indoleamine 2,3 Dioxygenase and Inducible Nitric Oxide Synthase in the Replication of Human Cytomegalovirus in Retinal Pigment Epithelial Cells
Bodaghi et al.
J. Immunol. 1999;162:957-964.
ABSTRACT | FULL TEXT  

Incidence of Foscarnet Resistance and Cidofovir Resistance in Patients Treated for Cytomegalovirus Retinitis
Jabs et al.
Antimicrob. Agents Chemother. 1998;42:2240-2244.
ABSTRACT | FULL TEXT  

Risk of developing CMV retinitis following non-ocular CMV end organ disease in AIDS patients
Verbraak et al.
Br J Ophthalmol 1998;82:748-750.
ABSTRACT | FULL TEXT  

Clinical Failure of CMV Retinitis With Intravitreal Cidofovir Is Associated With Antiviral Resistance
Smith et al.
Arch Ophthalmol 1998;116:178-185.
ABSTRACT | FULL TEXT  

MSL-109 Adjuvant Therapy for Cytomegalovirus Retinitis in Patients With Acquired Immunodeficiency Syndrome: The Monoclonal Antibody Cytomegalovirus Retinitis Trial
The Studies of Ocular Complications of AIDS Resear
Arch Ophthalmol 1997;115:1528-1536.
ABSTRACT  

Ganciclovir Implant Exchange: Timing, Surgical Procedure, and Complications
Martin et al.
Arch Ophthalmol 1997;115:1389-1394.
ABSTRACT  

HIV and AIDS and the Eye in Developing Countries: A Review
Lewallen and Courtright
Arch Ophthalmol 1997;115:1291-1295.
ABSTRACT  

Cidofovir
Jabs
Arch Ophthalmol 1997;115:785-786.
ABSTRACT  

Acquired Immunodeficiency Syndrome and the Eye-Reply
Jabs
Arch Ophthalmol 1997;115:293-293.
ABSTRACT  

Acquired Immunodeficiency Syndrome and the Eye--1996
Jabs
Arch Ophthalmol 1996;114:863-866.
ABSTRACT